OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing

Rhea-AI Summary

OptimizeRx (Nasdaq: OPRX) announced a data collaboration with Experian on January 7, 2026 to map OptimizeRx Micro-Neighborhood® audiences to Experian’s identity graph.

The integration enables deterministic onboarding, curated audience activation, and measurement designed to reduce audience loss and improve audience quality in privacy‑safe DTC healthcare marketing. Micro-Neighborhood® audiences target at ZIP+9 level across 35+ million U.S. micro-neighborhoods and are portable across major media channels for omnichannel activation and reporting.

Positive

• Deterministic identity mapping to Experian’s identity graph
• Targets at ZIP+9 granularity across 35+ million U.S. micro-neighborhoods
• Portable audiences across all major media channels for omnichannel activation

Negative

• None.

News Market Reaction

+3.98%

1 alert

+3.98% News Effect

On the day this news was published, OPRX gained 3.98%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current price: $13.32 Micro-Neighborhood coverage: 35+ million micro-neighborhoods Granularity level: ZIP+9 +5 more

8 metrics

Current price $13.32 Pre-news trading level vs 52-week range

Micro-Neighborhood coverage 35+ million micro-neighborhoods U.S. Micro-Neighborhood® audiences targeted at hyper-local level

Granularity level ZIP+9 Micro-Neighborhood® audience targeting granularity

Q3 2025 revenue $26.1M Third quarter 2025 results from prior earnings release

Q3 2025 gross profit $17.5M Third quarter 2025 financial results

FY2025 revenue guidance $105–$109M Raised full-year 2025 guidance from Nov 6, 2025 release

FY2026 revenue guidance $118–$124M Initial full-year 2026 revenue outlook

52-week range $3.9914–$22.25 One-year trading range prior to this news

Market Reality Check

Price: $12.85 Vol: Volume 176,407 is below t...

low vol

$12.85 Last Close

Volume Volume 176,407 is below the 20-day average of 270,396, suggesting a moderate reaction so far. low

Technical Shares at $13.32 are trading below the 200-day MA of $14.20 and 40.13% under the 52-week high.

Peers on Argus

OPRX gained 1.14% with below-average volume while close peers showed mixed moves...

1 Up

OPRX gained 1.14% with below-average volume while close peers showed mixed moves: several like NRC and DH were up, but SY declined and momentum scanners only flagged MNDR, indicating the move appears more stock-specific than broad sector-driven.

Historical Context

5 past events · Latest: Dec 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 17	Network expansion	Positive	+2.7%	New partner deals expanded point-of-care network and NPI reach by 37%.
Nov 06	Earnings and guidance	Positive	-1.1%	Q3 revenue growth, profitability, and raised FY2025–2026 guidance.
Oct 30	Earnings call details	Neutral	-4.6%	Announcement of date and access details for Q2 2025 results call.
Oct 20	Conference call setup	Neutral	+3.8%	Scheduling third quarter 2025 results call and replay information.
Sep 10	Conference participation	Neutral	-1.3%	Planned participation in a growth conference and investor meetings.

Pattern Detected

Recent news with clearly positive fundamentals has produced mixed reactions, with one aligned gain and one divergence selloff, while neutral conference-related items show small, inconsistent moves.

Recent Company History

Over the past several months, OPRX has reported solid operating progress. On Nov 6, 2025, Q3 2025 revenue reached $26.1M with strong gross profit and raised FY2025 guidance to $105–$109M revenue, plus FY2026 guidance of $118–$124M. A Dec 17, 2025 update highlighted four new partner agreements that expanded point-of-care reach by 37%. The new Experian collaboration continues this pattern of expanding data, reach, and measurability across healthcare marketing solutions.

Market Pulse Summary

This announcement expands OPRX’s data and identity capabilities by linking its Micro-Neighborhood® a...

Analysis

This announcement expands OPRX’s data and identity capabilities by linking its Micro-Neighborhood® audiences to Experian’s identity graph, aiming to reduce onboarding loss and improve audience quality. In the past year, OPRX reported Q3 2025 revenue of $26.1M and raised FY2025 guidance to $105–$109M, alongside a 37% increase in unique NPI reach. Investors may watch how quickly this collaboration drives measurable campaign lift and supports those growth targets.

Key Terms

identity resolution, identity graph, direct-to-consumer (DTC) marketing, programmatic ads, +4 more

8 terms

identity resolution technical

"Expectations for personalized, omnichannel, and privacy-safe DTC marketing continue to rise, but identity resolution has remained fragmented"

Identity resolution is the process of stitching together pieces of data—like email addresses, device IDs, purchase history and other signals—so a company can recognize when different interactions belong to the same person. For investors, it matters because better identity resolution improves marketing efficiency, customer measurement and fraud detection, which can raise revenue predictability and reduce compliance risk; think of it as turning scattered puzzle pieces into a single, usable customer portrait.

identity graph technical

"maps OptimizeRx Micro-Neighborhood® audiences to Experian’s identity graph, enabling seamless onboarding"

An identity graph is a structured map that links different identifiers—like email addresses, device IDs, and customer records—to the same person so a business can recognize and track that customer across channels. For investors it matters because it improves how accurately companies target customers, measure which marketing drives sales, detect fraud and value customer relationships, affecting revenue efficiency and regulatory or privacy risk.

direct-to-consumer (DTC) marketing technical

"Fragmentation that Limits Direct-to-Consumer (DTC) Campaign Visibility Expectations for personalized"

Direct-to-consumer (DTC) marketing is when a company promotes and sells its products or services straight to individual buyers rather than through middlemen like retailers or wholesalers. Think of it as a brand opening its own storefront instead of relying on a shop owner; for investors this matters because it can change how much it costs to get customers, how much margin the company keeps, and how much customer data and pricing control it has—factors that affect revenue growth and profitability.

programmatic ads technical

"Marketers may not be able to determine if programmatic ads reach brand-qualified consumers at scale"

Programmatic ads are the automated buying and selling of online advertising space using software, where algorithms match available ad spots with advertisers much like a stock-trading platform matches buyers and sellers. For investors, programmatic advertising matters because it can boost a media company’s revenue and profit margins through faster, more targeted sales while also concentrating data, platform dependence and privacy or regulatory risks that can materially affect future growth.

onboarding technical

"audience is usually lost during the media onboarding process Audience Quality (AQ) may not accurately"

Onboarding is the process a company uses to bring new customers, employees, partners or clients up to speed with its products, services and procedures so they can start getting value quickly. It matters to investors because efficient onboarding speeds revenue growth, reduces churn and lowers support costs—like giving a new neighbor a useful map and keys so they settle in fast—while poor onboarding can stall adoption and raise expenses.

audience quality technical

"Audience Quality (AQ) may not accurately represent actual audience composition"

Audience quality measures how relevant and engaged the people who receive or see a company’s communications or advertising are — essentially whether the audience is made up of real potential customers, investors, or decision-makers rather than random or uninterested viewers. For investors this matters because high-quality audiences make marketing and disclosure more likely to translate into sales, credible investor interest and reliable signals about demand, while low-quality audiences can waste resources and obscure the true market outlook.

omnichannel technical

"Expectations for personalized, omnichannel, and privacy-safe DTC marketing continue to rise"

A coordinated approach to selling and serving customers across all touchpoints—stores, websites, mobile apps, social media, and call centers—so the experience feels like one continuous conversation no matter where a customer interacts. For investors, omnichannel capability signals how well a company can attract and keep customers, turn interactions into sales, and use shared customer data to cut costs and boost revenue—making it a key driver of growth and competitive strength.

deterministic cohorts technical

"data to build deterministic cohorts aligned to brand eligibility signals"

Deterministic cohorts are groups of patients or data subjects defined by fixed, explicit rules (for example, specific diagnoses, lab values, or prescription patterns) that always include the same people when the same information is applied. For investors, deterministic cohorts matter because they make study results and product performance more reproducible and easier for regulators or buyers to verify—like using a precise recipe instead of a guess—to reduce uncertainty about what the numbers actually represent.

AI-generated analysis. Not financial advice.

Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data and technology company. This integration maps OptimizeRx Micro-Neighborhood^® audiences to Experian’s identity graph, enabling seamless onboarding and curated audience activation, delivering a transparent, reliable methodology for life sciences brands and healthcare marketing agencies to reach and measure consumer audiences at scale.

Addressing Fragmentation that Limits Direct-to-Consumer (DTC) Campaign Visibility

Expectations for personalized, omnichannel, and privacy-safe DTC marketing continue to rise, but identity resolution has remained fragmented and incomplete. As a result:

• Data and standard measurement practices typically omit a significant percentage of the exposed audience
• A notable portion of the target audience is usually lost during the media onboarding process
• Audience Quality (AQ) may not accurately represent actual audience composition
• Marketers may not be able to determine if programmatic ads reach brand-qualified consumers at scale
  
  

This visibility gap can prevent life sciences brands from accurately measuring the impact of their marketing campaigns and optimizing their targeting and tactics.

OptimizeRx and Experian’s Integrated Audience Mapping Closes the Visibility Gap

Integrating OptimizeRx’s patented, deterministic Micro-Neighborhood^® audience data with Experian’s identity graph enables audience expansion for onboarding, curation, and measurement through a deep set of identifiers, ensuring scale and maximum addressability in a privacy-forward fashion. The benefits for life science brands include:

• The ability to more accurately measure exposed audiences, for a more complete and transparent view of engagement and effectiveness
• Reduced audience loss during the onboarding process due to improved audience mapping, increasing total media reach
• Higher projected AQ and a significantly reduced gap between projected and actual AQ, for more accurate media planning
  
  

“We’re thrilled to give our life science and agency clients a uniquely integrated solution that combines Experian’s best-in-class consumer data and robust identity infrastructure with OptimizeRx’s patented, privacy-safe targeting methodology based on real-world healthcare data,” said Drew Teller, Director, Strategic Media Partnerships at OptimizeRx. “This collaboration enables brands to activate media against deterministic and data-driven Micro-Neighborhood^® audiences with greater confidence in audience quality and improved measurability across all channels.”

"Together, we are strengthening how life science marketers onboard and activate third-party audiences at scale,” said Colleen Dawe, Vice President of Advertiser Partnerships at Experian. “By connecting OptimizeRx’s Micro-Neighborhood^® audiences to Experian’s identity graph, we can reduce onboarding loss and support curation and measurement, delivering more addressable reach and the data for a more complete, privacy-forward view of campaign performance.”

About OptimizeRx Micro-Neighborhood^® Audiences

OptimizeRx’s Micro-Neighborhood^® audiences are privacy-compliant, hyper-local consumer audiences created using real-world, privacy-safe clinical and consumer data to build deterministic cohorts aligned to brand eligibility signals. Rather than broad or lookalike models, Micro-Neighborhood^® audiences target at ZIP+9 level granularity across 35+ million U.S. micro-neighborhoods, enabling highly precise segmentation of patients and their providers. Micro-Neighborhood^® audiences are portable across all major media channels and onboarders, so life science marketers can easily activate, manage, and report on omnichannel direct-to-consumer advertising.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative, AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood^® audiences to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life science companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on LinkedIn or X, or visit www.optimizerx.com.

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money.

We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,100 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "will", "may", "can", “enables”, or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the ability of OptimizeRx to measure a higher percentage of exposed audiences for a more complete and transparent view of campaign engagement and effectiveness, to expand audiences for onboarding, curation, and measurement, to ensure scale and addressability in a privacy-forward fashion, to reduce audience loss during the onboarding process, to reduce gaps between projected and actual AQ, to improve measurability across all audience channels, and to deliver more addressable reach.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligations to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. 

Contact Information: 

OptimizeRx Contact     
Jennifer Dinkel, VP Marketing  
jdinkel@optimizerx.com

Experian Contact 
 Jordan Takeyama
jordan.takeyama@experian.com

Press Inquiries 
Matter Communications  
optimizerx@matternow.com 
   

FAQ

What did OptimizeRx announce with Experian on January 7, 2026 for OPRX?

OptimizeRx announced a collaboration to map Micro-Neighborhood® audiences to Experian’s identity graph to improve onboarding and measurement.

How granular are OptimizeRx Micro-Neighborhood® audiences used in the OPRX and Experian integration?

Micro-Neighborhood® audiences target at ZIP+9 level granularity across 35+ million U.S. micro-neighborhoods.

How will the OPRX–Experian integration affect DTC campaign measurement?

The integration is designed to reduce audience loss during onboarding and improve audience quality for more complete campaign measurement.

Can life science marketers activate OptimizeRx audiences across channels after the Experian collaboration?

Yes; Micro-Neighborhood® audiences are portable across major media channels for omnichannel activation and reporting.

Does the OPRX announcement provide financial guidance or quantified performance improvements?

No; the announcement describes methodological and data benefits but does not disclose financial guidance or specific quantified performance changes.